Search results for "Pasireotide"

showing 10 items of 16 documents

Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

2018

Purpose: To evaluate the effect of pasireotide on β-cell and adipose function in patients with Cushing’s disease (CD). Methods: Clinical and hormonal parameters, insulin secretion evaluated by HOMA-β and by the area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycaemic hyperinsulinaemic clamp, were evaluated in 12 patients with active CD, before and after 6 and 12 months of pasireotide. In addition, a panel of adipokines including leptin (Ob), leptin/leptin receptor ratio (Ob/Ob-R ratio), adiponectin, resistin, visfatin, adipocyte fatty acid binding protein (AFABP) and non-esterified fatty acids (NEFAs) was evaluated at…

AdultBlood GlucoseMalemedicine.medical_specialtyDiabetes mellituInjections SubcutaneousEndocrinology Diabetes and MetabolismAdipose tissueAdipokine030209 endocrinology & metabolism030204 cardiovascular system & hematologySettore MED/13 - EndocrinologiaCohort StudiesYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyAdipokinesInternal medicineDiabetes mellitusAdipokinemedicineHumansInsulinPituitary ACTH HypersecretionLeptin receptorAdiponectinbusiness.industryLeptinBody WeightMiddle AgedCushing’s diseasemedicine.diseaseInsulin sensitivityHormonesPasireotidePasireotideTreatment OutcomeEndocrinologychemistryFemaleResistinInsulin ResistanceSomatostatinbusiness
researchProduct

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence st…

2019

Abstract Purpose Clinical trials have demonstrated the favorable efficacy/safety profile of pasireotide in patients with Cushing’s disease (CD). We report interim long-term results of an ongoing real-world evidence study of subcutaneous pasireotide in patients with CD. Methods Adults with CD receiving pasireotide, initiated before (prior-use) or at study entry (new-use), were monitored for ≤ 3 years during a multicenter observational study (http://clinicaltrials.gov identifier NCT02310269). Primary objective was to assess long-term safety of pasireotide alone or with other CD therapies. Results At the time of this interim analysis, 127 patients had received pasireotide (new-use, n = 31; pri…

AdultMalePediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercortisolism030209 endocrinology & metabolismDiseaseArticleSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInterimmedicineHumansMulticenter Studies as TopicIn patientPituitary ACTH Hypersecretionbusiness.industryPituitary ACTH hypersecretionCushing's diseaseMiddle AgedCushing’s diseasemedicine.diseasePasireotidePasireotideClinical trialTreatment OutcomePituitarychemistryHyperglycemiaFemaleLong term safetySafetySomatostatinbusiness030217 neurology & neurosurgeryPituitary
researchProduct

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

2019

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence. Thirty-two CD patients started pasireotide at the dose of 600 µg twice a day (bid) and with the chance of up-titration to 900 µg bid, or down-titration to 450 or 300 µg bid, on the basis of urinary cortisol (UC) levels or safety. Hormonal, clinical and metabolic parameters were measured at baseline and at 3-month and 6-month follow-up, whereas tumour size was evaluated at baseline and at 6-mont…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismUrinary system030209 endocrinology & metabolismDiseaseSomatostatin analoguesCushing’s disease; Medical treatment; Pasireotide; Pituitary tumour; Somatostatin analoguesBody Mass IndexYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusHumansMedicinePituitary NeoplasmsPituitary ACTH HypersecretionAdverse effectAgedmedicine.diagnostic_testbusiness.industryPituitary tumourCushing's diseaseMiddle AgedCushing’s diseasemedicine.diseaseMagnetic Resonance ImagingPasireotidePasireotideTreatment OutcomeItalychemistry030220 oncology & carcinogenesisCushing’s disease Medical treatment Pasireotide Pituitary tumour Somatostatin analoguesFemaleOriginal ArticleWaist CircumferenceSomatostatinbusinessLipid profileBody mass indexMedical treatment
researchProduct

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy

2022

Cushing’s disease (CD) causes diabetes mellitus (DM) through different mechanisms in a significant proportion of patients. Glucose metabolism has rarely been assessed with appropriate testing in CD; we aimed to evaluate hormonal response to a mixed meal tolerance test (MMTT) in CD patients and analyzed the effect of pasireotide (PAS) on glucose homeostasis. To assess gastro-entero-pancreatic hormones response in diabetic (DM+) and non-diabetic (DM–) patients, 26 patients with CD underwent an MMTT. Ten patients were submitted to a second MMTT after two months of PAS 600 µg twice daily. The DM+ group had significantly higher BMI, waist circumference, glycemia, HbA1c, ACTH le…

Blood GlucoseCushing’s disease; diabetes mellitus; incretin; mixed meal test tolerance test; pasireotidemixed meal test tolerance testGastric Inhibitory PolypeptideIncretinsCatalysisInorganic ChemistryGlucagon-Like Peptide 1HumansInsulinPhysical and Theoretical ChemistryPituitary ACTH HypersecretionMolecular BiologyMealsSpectroscopyGlycated HemoglobinpasireotideC-Peptidediabetes mellituOrganic Chemistrydigestive oral and skin physiologyGeneral MedicineCushing’s diseaseGlucagonincretinComputer Science ApplicationsDiabetes Mellitus Type 2Cushing’s disease; mixed meal test tolerance test; diabetes mellitus; incretin; pasireotidediabetes mellituspasireotide.Insulin ResistanceSomatostatinhormones hormone substitutes and hormone antagonists
researchProduct

A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) …

2013

4031 Background: The novel somatostatin analog (SSA) pasireotide has a broader binding profile than currently available SSA (octreotide and lanreotide). Results from a phase III study (NCT00690430) of pasireotide LAR (P) vs octreotide LAR (O) in patients (pts) with NET and disease-related symptoms uncontrolled by the maximum approved dose of available SSA are shown. Methods: Pts (N=110) were randomized and stratified by predominant symptom at baseline (diarrhea [D], flushing [F], or D+F) 1:1 to P (60 mg IM) or O (40 mg IM) q28d. Primary objective was symptom response at month (M) 6. Secondary objectives included tumor response and safety. Progression-free survival (PFS) was an exploratory …

Cancer Researchmedicine.medical_specialtybusiness.industryOctreotideDiseaseNeuroendocrine tumorsmedicine.diseaseLanreotideOctreotide larGastroenterologyPasireotidechemistry.chemical_compoundSomatostatinEndocrinologyOncologychemistryInternal medicineMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

2018

Introduction: Cushing’s disease (CD) is characterized by procoagulative profile. Treatment with cortisol-reducing medications might normalize the coagulation impairment potentially eliminating the risk of thromboembolic complications. Aim: The aim of this prospective study is to evaluate the effectiveness of 6–12 months of treatment with pasireotide (Signifor®, Novartis) 600 µg twice daily on coagulative factors in 21 patients (16 females, mean age 46 ± 12.2 years) with CD. Biochemical, hormonal (urinary free cortisol, UFC; late night salivary cortisol, LNSC; ACTH) and coagulative parameters as Protrombin time (PT), aPTT, factors VIII, IX and XI, antithrombin III, protein C, protein S, fibr…

Cortisol secretionAdultBlood GlucoseMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterologySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansProspective StudiesProspective cohort studyThromboprophylaxisPituitary ACTH HypersecretionBlood CoagulationClotting factorCoagulationbusiness.industryAnticoagulantCoagulation; Cushing’s disease; Pasireotide; Pituitary; Thromboprophylaxis; Endocrinology Diabetes and Metabolism; EndocrinologyCushing's diseaseCushing’s diseaseMiddle Agedmedicine.diseasePasireotidePasireotideDiabetes and MetabolismCoagulative necrosisTreatment OutcomechemistryPituitary030220 oncology & carcinogenesisConcomitantThromboprophylaxiFemaleBlood Coagulation TestsbusinessSomatostatinEndocrine
researchProduct

Modificazioni di insulino-secrezione, insulino-sensibilità e funzione adiposa durante terapia con pasireotide in un gruppo di pazienti con malattia d…

2016

Background: La terapia con pasireotide (PAS) è efficace nel miglioramento del quadro clinico e biochimico dei soggetti con Malattia di Cushing (MC) da adenoma ipofisario ACTH-secernente, ma una della principali cause di interruzione della stessa è l’insorgenza di eventi avversi, tra i quali l’iperglicemia è il più frequente. Obiettivi: Valutare l’effetto della terapia con PAS su metabolismo glucidico, insulino-secrezione e sensibilità. Metodi: Abbiamo valutato in 8 pazienti con MC recidivata post-chirurgia durante un follow-up terapeutico di 12 mesi, oltre ai parametri clinici ed ormonali, l’insulino-secrezione tramite HOMAβ e area sotto la curva del C-peptide (AUC2hc-peptide) durante MMTT,…

Cushing pasireotideSettore MED/13 - Endocrinologia
researchProduct

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available s…

2015

Edward M Wolin,1 Barbara Jarzab,2 Barbro Eriksson,3 Thomas Walter,4 Christos Toumpanakis,5 Michael A Morse,6 Paola Tomassetti,7 Matthias M Weber,8 David R Fogelman,9 John Ramage,10 Donald Poon,11 Brian Gadbaw,12 Jiang Li,12 Janice L Pasieka,13 Abakar Mahamat,14 Fredrik Swahn,15 John Newell-Price,16 Wasat Mansoor,17 Kjell Öberg3 1Markey Cancer Center, University of Kentucky, Lexington, KY, USA; 2Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland; 3Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden; 4Department of Medical Oncology, Ed…

MaleTime FactorsPharmaceutical ScienceOctreotideKaplan-Meier EstimateNeuroendocrine tumorsDigestive System NeoplasmsOctreotideGastroenterologychemistry.chemical_compoundDrug DiscoveryOdds RatioOriginal ResearchAged 80 and oversomatostatin analoguesDrug SubstitutionHazard ratioMiddle AgedTumor BurdenTreatment OutcomeFemalemedicine.symptomSomatostatinCarcinoid syndromemedicine.drugAdultmedicine.medical_specialtyNauseaCarcinoid tumorscarcinoid syndromeAntineoplastic AgentsCarcinoid TumorDisease-Free SurvivalDouble-Blind MethodInternal medicinemedicineHumansProgression-free survivalAgedProportional Hazards ModelsPharmacologypasireotideCancer och onkologiDrug Design Development and Therapybusiness.industrylcsh:RM1-950medicine.diseasesymptom controlPasireotidelcsh:Therapeutics. PharmacologyEndocrinologyLogistic ModelschemistryDrug Resistance NeoplasmDelayed-Action PreparationsCancer and Oncologyneuroendocrine tumorsbusinessprogression-free survival
researchProduct

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

2018

Abstract Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored. Current options include new pituitary surgery and/or radiosurgery, or alternative medical treatment with SRLs high dose regimens, pegvisomant (PEG) as monotherapy, or combined therapy with the addition of PEG or cabergoline to SRLs. A new pharmacological approach includes pasireotide, a second-generation SRL approved for patients who do not adequately respond to surgery and/or for whom surgery is not an option. No reports on efficacy and safety of combined therapy with pasireotide and p…

OncologyAdultMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPegvisomant030209 endocrinology & metabolismCase ReportAntineoplastic Agentslcsh:Diseases of the endocrine glands. Clinical endocrinologyRadiosurgerySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCombined treatmentCabergolineInternal medicineAcromegalymedicineHumansErgolinesSalvage TherapyCotreatmentlcsh:RC648-665Medical treatmentSomatostatin receptorbusiness.industryHuman Growth HormoneGeneral Medicinemedicine.diseasePrognosisResistantPasireotideHormonesPasireotidechemistry030220 oncology & carcinogenesisPegvisomantAcromegalyDrug Therapy CombinationAcromegaly; Cotreatment; Pasireotide; Pegvisomant; ResistantbusinessSomatostatinmedicine.drugBMC Endocrine Disorders
researchProduct